OverviewChartNewsTraderScreen

ENTERA BIO IS-,0000769/  IL0011429839  /

Frankfurt
27/05/2024  08:08:08 Chg. -0.0200 Volume Bid08:20:51 Ask08:20:51 High Low
2.0800EUR -0.95% 0
Turnover: 0.0000		 2.1000Bid Size: 500 2.2200Ask Size: 500 2.0800 2.0800
GlobeNewswire 15/05 Entera Bio Appoints Dr. Rachel B Wagman as Key Clinical Advisor and Scientific Advisory Board Member
GlobeNewswire 13/05 Entera Bio to Present Phase 1 Data from First-in-Class, PTH(1-34) Peptide Tablets (EB612) for the Tr...
GlobeNewswire 10/05 Entera Bio Reports Q1 2024 Financial Results and Provides Business Updates
GlobeNewswire 08/04 Entera Bio Announces Publication of Oral PTH(1-34) Peptide Tablets (EB613) Phase 2 Trial Data in the...
GlobeNewswire 26/03 Entera Bio Announces Key Regulatory Milestone for Oral PTH(1-34) Peptide (EB613) Phase 3 Program: FD...
GlobeNewswire 20/03 Entera Bio Announces Robust Pharmacokinetic Data for First-in-Class Oral GLP-2 Peptide Tablet Treatm...
GlobeNewswire 08/03 Entera Bio Announces Full Year 2023 Financial Results and Provides Business Updates
GlobeNewswire 04/03 Entera Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement
GlobeNewswire 30/01 Entera Bio to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
GlobeNewswire 03/01 Entera Bio Receives Extension from Nasdaq to Regain Compliance with Minimum Bid Price Rule
GlobeNewswire 26/12/2023 Entera Bio Announces Closing of Private Placement - Extends Cash Runway into 2025
GlobeNewswire 29/11/2023 Interim Results from Ongoing Clinical Study Confirm EB613 Optimized Profile for Osteoporosis Treatme...
GlobeNewswire 14/11/2023 Entera Bio Reports Q3 2023 Financial Results, Highlights Transformational Steps and Unveils Vision a...
GlobeNewswire 09/11/2023 Entera Bio Reports Key Milestone Relating to Oral PTH (1-34) Peptide (EB613) Phase 3 Program: ASBMR-...
GlobeNewswire 16/10/2023 Entera Bio Reports Rapid Pharmacodynamic (PD) Response and Consistent Pharmacokinetic (PK) Data for ...
GlobeNewswire 12/09/2023 Entera Bio Announces Collaboration with OPKO Biologics to Develop Oral Peptide Tablet Formulations f...
GlobeNewswire 05/09/2023 Entera Bio to Participate in Upcoming Investor Conferences
GlobeNewswire 16/08/2023 Entera Bio to Present Two Abstracts on its First-in-Class, Once Daily Oral hPTH(1-34) Peptide Tablet...
GlobeNewswire 08/03/2022 Entera Bio Reports Financial Results for the Year Ended December 31, 2021
GlobeNewswire 03/03/2022 Entera Bio to Report Business and Financial Results for the Year Ended December 31, 2021 on March 8,...
GlobeNewswire 17/02/2022 Entera Bio to Present at Aegis Virtual Conference on February 23rd
GlobeNewswire 04/01/2022 Entera Bio Announces Successful EB613 End-of-Phase 2 Meeting with FDA: FDA Agrees to Phase 3 Twelve ...
GlobeNewswire 10/11/2021 Entera Bio Reports Third Quarter 2021 Financial Results
GlobeNewswire 28/10/2021 Entera Bio Publishes Key Study Describing its Oral Delivery Technology Platform for Biologic Drugs
GlobeNewswire 06/10/2021 Entera Bio Presents Positive Phase 2 6-Month Bone Mineral Density Data for Oral PTH Formulation at L...